Relmada Therapeutics to Present at ROTH Capital Partners 27th Annual Growth Stock Conference

Company Presentation on March 11, 2015 at 3:00 PM Eastern Time.

NEW YORK, March 3, 2015 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that the Company's management will present at ROTH Capital Partners 27th Annual Growth Stock Conference, which is being held March 8-11, 2015 in Laguna Niguel, CA.

Relmada Therapeutics Corporate Logo

Sergio Traversa, CEO of Relmada Therapeutics, will present on Wednesday, March 11, 2015 at 12:00 p.m. PT (3:00 p.m. ET). 

Members of the investment community who are interested in meeting with Relmada's management team during the conference event should contact their ROTH representative or Christine Silverstein, director of investor relations at Relmada Therapeutics, at (212) 702-7167 or

A live webcast of Relmada's presentation will be available through the Company's website at Please register at least 10 minutes prior to the start of the presentation to ensure timely access. The webcast and presentation will also be archived on the website for 90 days after the conference.

For more information about the 27th Annual Roth Conference please contact or your ROTH representative at (800) 933-6830.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of pain. The Company has a diversified portfolio of four lead products at various stages of development including d-Methadone, its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; MepiGel, its orphan drug designated topical formulation of the local anesthetic mepivacaine; BuTab, its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER, its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. The Company's product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company's approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs. For more information, please visit Relmada's website at:

Forward-Looking Statements

This news release contains "forward-looking statements." These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


Investor Contact:
Michael Becker, SVP of Finance and Corporate Development
Relmada Therapeutics Inc.
Tel: 212-702-7169

Media Contact:

Maura McBride
Berry & Company Public Relations
Tel: 212-253-8881

Logo -


To view the original version on PR Newswire, visit:

SOURCE Relmada Therapeutics, Inc.